Biblio
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301-e311.
Change in Polistemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials. Turk J Haematol. 2023;40(4):266-268.
.